Novo Nordisk CEO predicts future of weight-loss drugs

Novo Nordisk’s CEO highlighted ongoing efforts to expand the use of GLP-1 medications for obesity treatment, noting that over 100 million Americans suffer from obesity and only a small percentage have used these drugs. He emphasized the potential for broader adoption to improve health outcomes and reduce healthcare costs, with ongoing development led by collaboration with artificial intelligence. The company sees significant growth potential as more people access these medications and their benefits extend beyond weight loss to economic productivity.

Size: 120%Text Size

Notice: This Is an AI-Generated Summary

Display The Full Article